<unk> , sold under the brand name Alofisel, is a medication to treat complex perianal fistulas in adults with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. It contains mesenchymal stem cells from fat tissue of adult donors. It was approved for use in the European Union in March 2018. The approval was spearheaded by data published in the ADMIRE-CD trial. It was approved for use in Japan by Japan's Ministry of Health, Labour and Welfare (MHLW) in September 2021.
Darvadstrocel
Methomyl
Lisocabtagene maraleucel
Nicogel
Triethylenetetramine
Ciltacabtagene autoleucel
Eptazocine
Mequitazine